Wugen, a biotech focused on allogeneic CAR-T therapies, raised $115 million in a financing round led by Fidelity Management & Research and supported by multiple investors. The proceeds will fund the advancement of WU-CART-007, targeting relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, with a pivotal trial underway aiming for a 2027 regulatory submission. Wugen’s allogeneic “off-the-shelf” approach utilizes donor cells, offering a potential curative option and addressing limitations of autologous CAR-T therapies. The company seeks to become the first to market such a therapy for T-cell malignancies.